

DAFTAR PUSTAKA

- Abdulhussain MM, Hasan NA, Hussain AG. The Inverse Correlation of MicroRNA-21 and MicroRNA-155 with the Tissue Inhibitor of Metalloproteinase 3 may Foster the Invasiveness of Breast Cancer. *International Journal of Medical Research & Health Sciences*. 2017; 6(12): 105-120.
- Abdulkareem IH. A Review on aetio-pathogenesis of breast cancer. *J Genet Syndr Gene Ther*. 2013; 4: 1-4.
- Agrawal AK, Jelen M, Rudnicki J, Grzebieniak Z, Zyśko D, Kielan W. The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type. *Folia Histochem Cytobiol*. 2010; 48: 26-9.
- Alsaed EF, Abdulkarim H, Tunio MA. Elevated preoperative serum cancer antigen 15.3 levels are associated with reduced disease-free survival: a single-institution experience. *Breast Cancer: Targets and Therapy* 2013; 5: 53–59.
- Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DSB. Direct serum assay for microRNA-21 concentration in early and advanced breast cancer. *Clinical Chemistry*. 2011; 57(1): 84-91.
- Ashariati A, 2019. *Manajemen Kanker Payudara Komprehensif*, editor : Sedana MP, Bintoro UY, Diansyah MN, Amrita PNA, Savitri M, Romadhon PZ, Permatasari A, Airlangga University Press, Surabaya, hlm 1-55
- Badr FM. Potential role of miR-21 in breast cancer diagnosis and therapy. *JSM Biotechnol Bioeng*. 2016; 3(5): 1068-76.

- Balic M, Thomssen C, Wurrstlein R, Gnant M, Harbeck N. St Gallen/Vienna 2019: a brief summary of the consensus discussion on the optimal primary breast cancer treatment. *Breast Care*. 2019; 14:103-110.
- Brey F, Ferlay J, Soerjomataram I, Siegel RL, Lindsey A, Torre JA. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *Cancer J Clin*. 2018; 68:394-424.
- Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4). *Annals of Oncology*. 2018; 29 (8): 1634-57.
- Carnero A, Jesus M. Paramio. The PTEN/PI3K/AKT pathway *in vivo*, cancer mouse models. *Frontiers in Oncology. Cancer Genetics*. 2014; 4: 252
- Checka CM, Chun JE, Scnabel FR. The Relationship of mamographic density and age : Implication for breast cancer screening. *AJR Am J Roentgenol*. 2012; 198: 292-295.
- Coombes AS. Endocrine-responsive breast cancer and strategies for combating resistance. *Nat Rev Cancer*. 2002; 2, 101-112.
- Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L. Intracellular and extracellular microRNAs in breast cancer. *Clinical Chemistry*. 2011; 57(2): 18-32.
- Cuk K, Zucknick M, Heil Jog, Dharanija M, Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, Junkermann H, Schneeweiss A, Burwinkel B. Circulating microRNA in plasma as early detection markers for breast cancer. *Int J of Cancer*. 2013; 132: 1602-1612.

- DeGraffenried LA, Fulcher L., Friedrichs W.E, Grünwald W, Ray RB, Hidalgo M, Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway, *Annals of Oncology* 15: 1510–1516, 2004 doi:10.1093/annonc/mdh388.
- Duffy MJ. Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?. *Clinical Chemistry*. 2006; 52:3 345–351.
- Ebeling FG, Stieber P, Untch M et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. *Br J Cancer*. 2002; 86:1217-1222.
- Enders KO, Rufina L, Shin VY, Jin HC, Candy PH, Edmond SK, Pang MR, Chua D, Chu KM, Law WL, Simon YK, Poon RTP, Kwong A. Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection, *PLoS ONE* 8(1): e53141.doi:10.1371/journal.pone.0053141
- Fattah HIA, Mahmoud NH, Elzoghby DM, Matar M, El-Shaer IM. Clinical utility of circulating microRNA-21 in breast cancer. *Egyptian J of Hosp Med*. 2018; 71(4): 2950-2955.
- Fu SW, Chen L, Man YG. MiRNA biomarkers in breast cancer detection and management. 2011; 2(1): 116-124.
- Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum miR-21 in breast cancer compared with CA 15-3 dan CEA. *Clin J Cancer Res*. 2013; 25(6): 743-48.
- Gao Y, Cai Q, Huang Y, Li S, Yang H, Sun L, Chen K, Wang Y. MicroRNA-21 as a potential diagnostic biomarker for breast cancer patients : a pooled analysis of individual studies. *Oncotarget*. 2016; 7(23): 98-105.

- Gnant M, Haebeck N, Thomssen C. St Gallen/Vienna 2017 : a brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment. *Breast Care*. 2017; 12:102-107.
- Guadagni F, Ferroni P, Carlini S et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. *Clin Cancer Res*. 2001; 7:2357-2362.)
- Hamam R, Ali AM, Alsaleh KA, Kassem M, Alfayez M, Aldahmash Aalajezi NM. MicroRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. *Scientific Reports*. 2016; 6(1): 1-7.
- Hamam R, Hamam D, Alsaleh KA, Kassem M, Zaher W, Alfayez M, Aldahmash A, Alajezi NM. Circulating microRNAs in breast cancer : novel diagnostic and prognostic biomarkers. *Cell Death & Disease*. 2017; 8(1): 23-34.
- Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *J Clin Oncol* 2007; 25:5287-312.
- Han JG, Jiang DY, Zhang CH, Yang YM, Pang D, Song YN, Zhang GQ. A novel panel of serum miR-21, miR-155, miR-365, as a potential diagnostic biomarkers for breast cancer. *Ann Surg Treat Res*. 2017; 92(2): 55-66.
- Halvorsen A. R., Helland A., Gromov P., Wielenga V.T, Møller T.M.L., Brunner N., Sandhu V., Anne-Lise Børresen-Dale, Gromova I,† and Haakensen V. D., Profiling of microRNAs in tumor interstitial fluid of breast tumors – a novel resource to identify biomarkers for prognostic classification and detection of cancer, *Molecular Oncology*. 2016. doi:10.1002/1878-

0261.12025

Hashim ZM. The Significance of CA15-3 in Breast Cancer Patients and Its Relationship to HER-2 Receptor Status. *International Journal of Immunopathology and Pharmacology*. 2014; 27(1): 45-51.

Hassiotou F, Geddes D. Anatomy of the human mammary gland: Current status of knowledge. *Clin Anat*. 2013; 26: 29-48.

Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as novel biomarkers for breast cancer. *Journal of Oncology*. 2010; 2(15): 9-16.

Huang GL, Zhang XH, Guo GL, Huang KT, Yan K, Yang KY, Shen X, You J, Hu XQ. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. *Oncology Reports*. 2009; 21: 673-679.

International Programme on Chemical Safety Biomarkers in Risk Assessment: Validity and Validation. Geneva: World Health Organization, 2001

Irvan, Febyan, Suparto, Sepsis dan Tata Laksana Berdasar Guideline Terbaru, *Jurnal Anestesiologi Indonesia*, Volume X, Nomor 1, Tahun 2018, hal 62-73

Jemal A, Brey F, Center MM, et al. Global cancer statistic. *CA Cancer J Clin*. 2011; 61: 69-90.

Juwita, Ompusunggu HES, Nauphar D, Pardede SM, Lim H, Siregar Y. Mir-21 ekspresi in grade I, II, III breast cancer. *Indonesian J of Med*. 2016; 1(1): 26-33.

- Juwita. MicroRNA-21, MicroRNA-155, MicroRNA-10B bagaimana perannya pada kanker payudara?. *J Kedokteran Syiah Kuala*. 2017. 17(2): 119-25.
- Kayani MR, Kayani MA, Malik FA, Faryal R. Role of miRNAs in breast cancer. *Asian Pacific J of Cancer Prev*. 2011; 12: 3175-79.
- Kementrian Kesehatan RI. Panduan Nasional Penanganan Kanker 2015. Kanker Payudara.
- Kementrian Kesehatan RI. Profil kesehatan Indonesia tahun 2012. <http://www.depkes.go.id/profil-kesehatanp-indonesia-tahun-2012.pdf>.
[diakses pada tanggal 20/02/2019](#).
- Kenemans P, Verstraeten RA, Verheijen RHM. Oncogenic pathways in hereditary and sporadic breast cancer. *Maturitas*. 2004; 49: 34–43.
- Kim YK. Extracellular microRNAs as biomarkers in human disease. *CMJ*. 2015; 51(2): 51-58.
- Klinge CM. Non-Coding RNAs in Breast Cancer: Intracellular and Intercellular Communication, *Non-coding RNA* 2018, 4, 40; doi:10.3390/ncrna4040040, www.mdpi.com/journal/ncrna
- Kufe DW. MUC1-C Oncoprotein as a Target in Breast Cancer; Activation of Signaling Pathways and Therapeutic Approaches. *Oncogene*. 2013; 32(9): 1073–1081. doi:10.1038/onc.2012.158.
- Kumar S, Keerthana R, Pazhanimuthu A, Perumal P. Overekspresi of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patient. *Indian J of Biochemistry & Biophysics*. 2013; 50: 210-214.
- Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H and Horiguchi J, Recent trends in microRNA research into breast cancer with particular

focus on the associations between microRNAs and intrinsic subtypes, *Journal of Human Genetics* (2017) 62, 15–24; doi:10.1038/jhg.2016.89

Kos T, Aksoy S, Sendur MAN, Arik Z, Civelek B, Kandemir N, Ozdemir NY, Zengin N, Altundag K, Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes, *JBUON* 2013; 18(3): 608-613) D.M.F. Pons-Anicet, B.P. Krebs, R. Mira & M. Namer, Value of CA 15:3 in the follow-up of breast cancer patients, *Br. J. Cancer* (1987), 55, 567-569)

Lebok P., Kopperschmidt V., Kluth M., C. Hube-Magg, C. Özden, Taskin B., K. Hussein, A. Mittenzwei, A. Lebeau, I. Witzel, L. Wölber, S. Mahner, F. Jänicke, S. Geist, P. Paluchowski, C. Wilke, U. Heilenkötter, Ronald Simon, Guido Sauter, L. Terracciano, R. Krech, A. von d. Assen, V. Müller and E. Burandt. Partial PTEN deletion is linked to poor prognosis in breast cancer. *BMC Cancer*. 2015; 15:963 DOI 10.1186/s12885-015-1770-3

Liang F, Yang M, Tong N, Fang J, Pan Y, Li J, Zhang X. Identification of six key miRNAs associated with breast cancer through screening large-scale microarray data. *Oncology Letter*. 2018; 16: 4159-4168

Li S, Shen Y, Wang M, Yang J, Lv M, Li P, Chen Z, Yang J, Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis, *Oncotarget*, 2017, Vol. 8, (No. 19), pp: 32043-32054

Li W, Zhang T, Guo L, Huang L. Regulation of PTEN expression by noncoding RNAs. *Journal of Experimental & Clinical Cancer Research*. 2018; 37: 223

- Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A and Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. *PLoS One* 2009; 4: e6229.
- Mar'Aguilara F, Jorge A. Mendoza-Ram'ireza, Ismael Malag'on-Santiago, Perla K. Espino-Silvad, Sandra K. Santuario-Facioc, Pablo Ruiz-Floresd, Cristina Rodr'iguez-Padillab and Diana Res'endez-P'ereza, Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. *Disease Markers*. 2013; 34: 163–169.
- McDermott AM, Miller N, Wall D, Martyn LM, Ball G. Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer. 2014. *PLoS ONE* 9(1): e87032. doi:10.1371/journal.pone.0087032
- Mehrgou A, Akouchekian M. Therapeutic impacts of microRNAs in breast cancer by their roles in regulating processes involved in this disease. *J Res Med Sci* 2017; 22:130.
- Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman KW, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS. Circulating microRNAs as stable blood-based markers for cancer detection. *PNAS*. 2008; 105(30): 513-518.
- Ng EKO, Li R, Shin VY, Jin HC, Leung CP, Ma ES, Pang R, Chua D, Chu KM, Law SY, Poon RT, Kwong A. Circulating microRNA as specific biomarkers for breast cancer detection. *PLOS One*. 2013; 8(1): 1-13.
- Pal M, Pat L. BRCA1 and miRNA : an emerging therapeutic target and intervention tool in breast cancer. *J pharm sci tech*. 2013; 3(1): 9-19.

- Pan X, Wang ZX, Wang R. MicroRNA-21 A novel therapeutic target in human cancer, *Cancer Biology & Therapy* 10:12, 1224-1232; December 15, 2010
- Pan X, Wang ZX, Wang R. MicroRNA-21 a novel therapeutic target in human cancer. *Cancer Biology & Therapy*. 2010; 10(12): 1224-32.
- Park BW, Oh JW, Kim JH, Park SH, Kim KS, Lee KS. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. *Ann Oncol* 2008;19:675-681
- Pons-Anicet D.M.F. , B.P. Krebs, R. Mira & M. Namer, Value of CA 15:3 in the follow-up of breast cancer patients, *Br. J. Cancer* (1987), 55, 567-569
- Rajabi H, Alam M, Takahashi H, Kharbanda A, Guha M, Ahmad R et al. MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial mesenchymal transition. *Oncogene* 2014;33:1680-9.
- Ravelli A & Reuben James M. & Lanza F & Anfossi S & Cappelletti Maria Rosa & Zanotti L & Gobbi A. & Senti C. & Brambilla P. & Milani M. & Spada D. & Pedrazzoli P. & Martino M. & Bottini A. & Generali D. & on behalf of the Solid Tumor Working Party of European Blood and Marrow Transplantation Society (EBMT); Breast cancer circulating biomarkers: advantages, drawbacks, and new insights, *Tumor Biol*. 2015, DOI 10.1007/s13277-015-3944-7
- Rietdorf S. Detection of microRNAs in circulating tumor cells. *Transl Cancer Res*. 2018; 7(2): 197-208.
- Sarvari G. Sandya Rani B., Bitla AR. Breast cancer diagnosis – role of biomarkers. *J Clin Sci Res*. 2017; 6:225-36. DOI: <http://dx.doi.org/10.15380/2277-5706.JCSR.17.08.005>

- Schwarzenbach H & Gahan PB. MicroRNA shuttle from cell-to-cell by exosomes and its impact in cancer. *Non-coding RNA*. 2019; 5: 1-22.
- Senkus E, Kyriakides S, Ohno S, Penault-Llorca F et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 2015; 26 (5): v8-v30.
- Shao Y, Sun X, He Y, Liu C, Liu H. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. *PLoS One*. 2015; 10: 13-18.
- Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. Mir-21 mediated tumor growth oncogene. 2007; 26: 2799-2803.
- Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, Hu C. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. *J Cancer Res Clin Oncol*. 2013; 139: 223-229.
- Soleimanpour E, Babaei E, Feizi MAH, Montazeri V. Circulating miR-21 and miR-155 as potential noninvasive biomarkers in Iranian Azeri patients with breast carcinoma. *J Can Res Ther*. 2019; 15: 1092-7.
- Stieber P, Nagel D, Blankenburg I, Heinemann V, Untch M, Bauerfeind I, Di Gioia D. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer – a retrospective analysis of kinetics on 743 breast cancer patients. *Clinica Chimica Acta*. 2015; doi: 0.1016/j.cca.2015.06.022.
- Tang Y, Zhou X, Ji J, Chen L, Cao J, Luo J, Zhang S. High expression levels of miR-21 and miR-210 predict unfavourable survival in breast cancer : a

- systemic review and meta-analysis. *Int J Biol Markers*. 2015; 30(4): 347-58.
- Torre L, Bray F, Siegel R, et al. Global cancer statistic. *Cancer J Clin*. 2015; 65(2): 87-108.
- Trivedi HP, Aizaz KM, Parmar S. Correlation between Tumour Marker CA 15-3 Level and TNM Staging in Breast Cancer. *International Journal of Health Sciences & Research*. 2016; 47 (6): 5.
- Tsai HP, Huang SF, Li CF, Chien HT, Chen SC (2018) Differential microRNA expression in breast cancer with different onset age. *PLoS ONE* 13(1): e0191195. <https://doi.org/10.1371/journal.pone.0191195>
- Uehara M, Kinoshita T, Hojo T, et al. Long term prognostic study of carcinoembryonic antigen (CEA) and Carbohydrate antigen 15-3 (CA 15-3) in breast cancer. *Int J Clin Oncol*. 2008; 13: 447-451.
- Usmani A, Shoro AA, Memon Z, Hussain M, Rehman R. Diagnostic, prognostic, and predictive value of microRNA-21 in breast cancer patients, their daughters and healthy individuals. *Am J Cancer Res*. 2015; 5(8): 2484-90.
- PLOS One*. 2015; 2: 1-15.
- Visvader, J.E., 2009. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. *Genes Dev* 23, 2563-2577.
- Wang Y, Zhang Y, Pan C, Ma F, Zhang S. Prediction of poor prognosis in breast cancer patients based on micro RNA-21 expression : a meta-analysis.
- Wang G, Wang L, Sun S, Wu J, Wang Q. Quantitative measurement of serum microRNA-21 expression in relation to breast cancer metastasis in chinese females. *Ann Lab Med*. 2015; 35; 226-32.

- Yan L.X , Huang, XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, And Shao JY, MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis, RNA (2008), 14:2348–2360
- Yanwirasti, Harahap WA, Arisanty D. Evaluation of miR-21 and miR-10b expression of human breast cancer in west sumatra. Pak J Biol Sci. 2017. 20(4): 189-96.
- Zhang J, Jiang C, Shi X, Yu H, Lin H, Peng Y. Diagnostic value of circulating miR-155, miR-21, and miR-10b as promising biomarkers in human breast cancer. Int J Clin Exp Patol. 2016; 9(10): 10258-65.
- Zhao H, Shen J, Medico L, Wang D, Ambrosone CB and Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 2010; 5: e13735.A.M. Kabel / Journal of Oncological Sciences 3 (2017) 5-11, Tumor markers of breast cancer: New prospectives)
- Zhu R, Dong YH, Yu HL. Prognostic value of miR-21 in patients with breast cancer : a meta-analysis. Int J Clin Exp Med. 2016; 9(2): 2017-26.
- Zhu S, Wu H, Wu F, Wie D, Shang S, Mo YY. MicroRNA-21 targets tumor supressor genes in invasion and metastasis. J Cell Res. 2008; 18: 350-59.
- Zhang WZ, Li Y, Wu X. Value of combined detection of serum miR-21, miR-195 and miR-222 in the diagnosis of early breast cancer. Journal of Hainan Medical University. 2016; 22(14): 128-130.